{
    "clinical_study": {
        "@rank": "3220", 
        "acronym": "BLAST-AHF", 
        "arm_group": [
            {
                "arm_group_label": "TRV027 dose #1", 
                "arm_group_type": "Experimental", 
                "description": "TRV027 dose #1 via continuous IV infusion"
            }, 
            {
                "arm_group_label": "TRV027 dose #2", 
                "arm_group_type": "Experimental", 
                "description": "TRV027 dose #2 via continuous IV infusion"
            }, 
            {
                "arm_group_label": "TRV027 dose #3", 
                "arm_group_type": "Experimental", 
                "description": "TRV027 dose #3 via continuous IV infusion"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo via continuous IV infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the overall safety and efficacy of TRV027 when administered in addition to\n      standard of care (SOC) on mortality, morbidity, dyspnea, and length of stay in patients\n      hospitalized with Acute Decompensated Heart Failure (ADHF)."
        }, 
        "brief_title": "A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Decompensated Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men or women aged \u226521 years and \u2264 85 years 1a.Women of non-child-bearing potential\n\n          2. Able to provide written informed consent\n\n          3. Pre-existing diagnosis of heart failure\n\n          4. Systolic blood pressure \u2265120 mmHg and \u2264 200 mmHg within 30 minutes of  randomization\n\n          5. Ventricular rate \u2264125 bpm. Patients with rate-controlled persistent or permanent\n             atrial fibrillation (aFib) at screening are permitted.\n\n          6. Presence of ADHF defined by:\n\n               -  BNP > 400 pg/mL or NT-proBNP > 1600 pg/mL\n\n                    -  For patients with BMI >30 kg/m2: BNP > 200 pg/mL or NT-proBNP > 800 pg/mL\n\n                    -  For patients with rate-controlled persistent or permanent aFib: BNP > 600\n                       pg/mL or NT-proBNP > 2400 pg/mL\n\n             AND at least two (2) of the following:\n\n               -  Congestion on chest radiograph (CXR)\n\n               -  Rales by chest auscultation\n\n               -  Edema \u2265 +1 on a 0-3 + scale, indicating indentation of skin with mild digital\n                  pressure that requires 10 or more seconds to resolve in any dependent area\n                  including extremities or sacral region.\n\n               -  Elevated jugular venous pressure (\u22658 cm H2O)\n\n          7. Receipt of a IV loop diuretic at a minimum dose 40 mg furosemide (or equivalent loop\n             diuretic) for the treatment of dyspnea due to ADHF at least 1 hour prior to\n             anticipated  randomization and the initiation of study medication\n\n          8. Patient report of dyspnea at rest or upon minimal exertion during screening at least\n             one hour after administration of IV loop diuretic\n\n        Exclusion Criteria:\n\n          1. Women who are pregnant or breast-feeding\n\n          2. Clinical presentation:\n\n               1. ACS in the 3 months prior to screening or planned during current admission.\n\n               2. Temperature >38.5oC\n\n               3. Clinically significant anemia\n\n               4. Current or planned ultrafiltration, paracentesis, hemofiltration or dialysis at\n                  time of screening\n\n               5. Any mechanical ventilation\n\n               6. CPAP/BiPAP discontinued less than 1 hour prior to randomization\n\n               7. History of primary pulmonary hypertension\n\n               8. History or current use of left ventricular assist devices (LVADs) or\n                  intra-aortic balloon pumps (IABPs)\n\n               9. Intravenous radiographic contrast agent within 72 hours prior to screening or\n                  presence of acute contrast induced nephropathy at the time of screening\n\n              10. Presence of clinically significant arrhythmia\n\n          3. Medications:\n\n               1. nitroprusside or nesiritide\n\n               2. Intravenous nitrates\n\n               3. use of inotropes\n\n               4. Use of ARBs within 7 days of prior to randomization\n\n               5. Use of any investigational medication within 30 days\n\n               6. clinically significant hypersensitivity or allergy to, or intolerance of,\n                  angiotensin receptor blockers\n\n          4. Medical history:\n\n               1. Major surgery within 8 weeks prior to screening\n\n               2. Stroke within 3 months prior to screening\n\n               3. eGFR (sMDRD) <20 mL/min/1.73m2 or >75 mL/min/1.73m2 between presentation and\n                  randomization\n\n               4. Post cardiac or renal transplant\n\n               5. Listed for renal transplant or cardiac transplant with anticipated transplant\n                  time to transplant < 6 months\n\n               6. History of severe left ventricular outlet obstruction (either valvular or\n                  sub-valvular), severe mitral valve stenosis or severe aortic regurgitation\n\n               7. Cardiac valvular abnormality that requires surgical correction\n\n               8. Complex congenital heart disease\n\n               9. Hypertrophic or restrictive cardiomyopathy\n\n              10. significant pulmonary or hepatic disease that could interfere with the\n                  evaluation of safety or efficacy of TRV027\n\n              11. life expectancy of less than 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01966601", 
            "org_study_id": "CP027.2002"
        }, 
        "intervention": [
            {
                "arm_group_label": "TRV027 dose #1", 
                "description": "TRV027 continuous intravenous infusion Dose #1", 
                "intervention_name": "TRV027 Dose #1", 
                "intervention_type": "Drug", 
                "other_name": "Formerly known as TRV120027"
            }, 
            {
                "arm_group_label": "TRV027 dose #2", 
                "description": "TRV027 continuous intravenous infusion Dose #2", 
                "intervention_name": "TRV027 Dose #2", 
                "intervention_type": "Drug", 
                "other_name": "Formerly known as TRV120027"
            }, 
            {
                "arm_group_label": "TRV027 dose #3", 
                "description": "TRV027 continuous intravenous infusion Dose #3", 
                "intervention_name": "TRV027 Dose #3", 
                "intervention_type": "Drug", 
                "other_name": "Formerly known as TRV120027"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo continuous intravenous infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Wayne State University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "University of Cincinnati"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tullahoma", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37388"
                    }, 
                    "name": "Tennessee Center for Clinical Trials"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Michael E Debakey VA Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Hungary"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure", 
        "overall_contact": {
            "email": "clinicaltrials@trevenainc.com", 
            "last_name": "Clinical Operations"
        }, 
        "overall_official": {
            "affiliation": "Trevena Inc.", 
            "last_name": "David Soergel, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary clinical endpoint is a  of the following outcomes: (1) time from randomization to death through day 30, (2) time from randomization to heart failure re-hospitalization through day 30, (3) time from randomization to worsening heart failure through day 5, (4) change in dyspnea VAS score (calculated area under the curve) from baseline through day 5, and (5) length of initial hospital stay (in days) from randomization.  The component outcomes will be combined by deriving an average Z for each patient.", 
            "measure": "composite z score", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01966601"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Trevena Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Trevena Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}